丝裂霉素微球-经动脉栓塞化疗联合经皮乙醇注射治疗肝细胞癌
[SMANCS-TAE combined with PEI in the treatment for hepatocellular carcinoma].
作者信息
Numata K, Tanaka K, Kiba T, Saito S, Morita K, Kitamura T, Kondo M, Morimoto M, Shirato K, Hori A, Shimamura T, Isozaki T, Arata S, Okazaki H, Fujii T, Sekihara H
机构信息
Dept. of Third Internal Medicine, Yokohama City University School of Medicine.
出版信息
Gan To Kagaku Ryoho. 1998 Feb;25 Suppl 1:141-5.
From January 1996 to August 1997, 24 patients with advanced hepatocellular carcinoma (HCC) equal to or more than 2 cm (mean +/- SD; 4.1 +/- 3.0 cm) in main tumor diameter were treated by SMANCS-TAE (20 cases) or SMANCS-TAI (4 cases) combined with PEI. Six cases had solitary lesion, 16 cases had multiple lesions, and 2 cases had massive lesions. After this combination therapy, 21 of 24 cases had complete tumor necrosis. During 3 to 19 months follow up period, 12 cases had cancer-free survival (SMANCS-TAI; 3 cases), and 9 cases had tumor recurrences (3 cases were local recurrences and 6 cases involved new lesions). Two cases died of hepatic infarction and cancer death, however, the remaining 22 cases were surviving. SMANCS-TAE combined with PEI is useful treatment for advanced large or multiple HCC lesions in patients who are poor surgical risks.
1996年1月至1997年8月，对24例主要肿瘤直径等于或大于2 cm（平均±标准差；4.1±3.0 cm）的晚期肝细胞癌（HCC）患者采用丝裂霉素超液化碘油肝动脉栓塞化疗（SMANCS-TAE，20例）或丝裂霉素超液化碘油肝动脉灌注化疗（SMANCS-TAI，4例）联合经皮乙醇注射（PEI）治疗。6例为单发病灶，16例为多发病灶，2例为巨块型病灶。联合治疗后，24例中有21例肿瘤完全坏死。在3至19个月的随访期内，12例无癌生存（SMANCS-TAI；3例），9例肿瘤复发（3例为局部复发，6例出现新病灶）。2例死于肝梗死和癌症，其余22例存活。对于手术风险高的晚期大肝癌或多发HCC病灶患者，SMANCS-TAE联合PEI是一种有效的治疗方法。
Zotero 插件